In this study, we investigated pretreatment serum IL-18 and sIL-2R levels in DLBCL patients treated with R-CHOP as prognostic factors with respect to OS, DFS, CR rates. This evidence concerns the gene IL18 and diffuse large B-cell lymphoma.